This wiki has undergone a migration to Confluence found Here
Difference between revisions of "2017-08-10 Patient Care FHIR Call"
Jump to navigation
Jump to search
(50 intermediate revisions by the same user not shown) | |||
Line 53: | Line 53: | ||
|- | |- | ||
<!-- ********add attendee information here *********--> | <!-- ********add attendee information here *********--> | ||
− | | || Elaine Ayres | + | |X || Elaine Ayres |
|colspan="2"| NIH/Department of Clinical Research Informatics | |colspan="2"| NIH/Department of Clinical Research Informatics | ||
|- | |- | ||
− | | || Dave Carlson | + | |X || Dave Carlson |
|colspan="2"| VA | |colspan="2"| VA | ||
|- | |- | ||
− | | | + | | X || Stephen Chu |
|colspan="2"| The Australian Digital Health Agency (ADHA) | |colspan="2"| The Australian Digital Health Agency (ADHA) | ||
|- | |- | ||
Line 65: | Line 65: | ||
|colspan="2"| EMI Advisors LLC | |colspan="2"| EMI Advisors LLC | ||
|- | |- | ||
− | | || Eric Haas | + | |X || Eric Haas |
|colspan="2"| Haas Consulting | |colspan="2"| Haas Consulting | ||
|- | |- | ||
− | | || Rob Hausam | + | |X || Rob Hausam |
|colspan="2"| Hausam Consulting LLC | |colspan="2"| Hausam Consulting LLC | ||
|- | |- | ||
− | | || Laura Heermann-Langford | + | | X|| Laura Heermann-Langford |
|colspan="2"| Intermountain Healthcare | |colspan="2"| Intermountain Healthcare | ||
|- | |- | ||
− | | || Emma Jones | + | | X|| Emma Jones |
|colspan="2"| Allscripts | |colspan="2"| Allscripts | ||
|- | |- | ||
Line 80: | Line 80: | ||
|colspan="2"| InterSystems | |colspan="2"| InterSystems | ||
|- | |- | ||
− | | | + | | X || Tony Little |
|colspan="2"| Optum 360 | |colspan="2"| Optum 360 | ||
|- | |- | ||
− | | || Jay Lyle | + | |X || Jay Lyle |
|colspan="2"| Ockham Information Services LLC, VA | |colspan="2"| Ockham Information Services LLC, VA | ||
|- | |- | ||
Line 95: | Line 95: | ||
|colspan="2"| Cerner | |colspan="2"| Cerner | ||
|- | |- | ||
− | | | + | | X || Michelle M Miller |
|colspan="2"| Cerner | |colspan="2"| Cerner | ||
|- | |- | ||
Line 107: | Line 107: | ||
|colspan="2"| Cognosante | |colspan="2"| Cognosante | ||
|- | |- | ||
− | | || Mike Padula | + | | X|| Mike Padula |
|colspan="2"| The Children's Hospital of Philadelphia | |colspan="2"| The Children's Hospital of Philadelphia | ||
|- | |- | ||
Line 113: | Line 113: | ||
|colspan="2"| Intermountain Healthcare | |colspan="2"| Intermountain Healthcare | ||
|- | |- | ||
− | | || Joe Quinn | + | | X|| Joe Quinn |
|colspan="2"| Optum | |colspan="2"| Optum | ||
|- | |- | ||
Line 143: | Line 143: | ||
|colspan="2"| | |colspan="2"| | ||
|- | |- | ||
− | | || Melva Peters | + | |X || Melva Peters |
|colspan="2"| Gevity | |colspan="2"| Gevity | ||
|- | |- | ||
− | | || John Hatem | + | |X || John Hatem |
|colspan="2"| | |colspan="2"| | ||
|- | |- | ||
Line 152: | Line 152: | ||
|colspan="2"| | |colspan="2"| | ||
|- | |- | ||
− | | || Scott Robertson | + | |X || Scott Robertson |
|colspan="2"| | |colspan="2"| | ||
|- | |- | ||
Line 159: | Line 159: | ||
|- | |- | ||
| || Grahame Grieve | | || Grahame Grieve | ||
+ | |colspan="2"| | ||
+ | |- | ||
+ | | X|| Daniel Rutz | ||
|colspan="2"| | |colspan="2"| | ||
|- | |- | ||
Line 184: | Line 187: | ||
#Agenda review | #Agenda review | ||
#Approve previous meeting minutes [[2017-08-03_Patient_Care_FHIR_Call]] | #Approve previous meeting minutes [[2017-08-03_Patient_Care_FHIR_Call]] | ||
− | #*'''Motion:''' | + | #*'''Motion:''' Stephen/Eric |
# OO/PC/Pharmacy Joint Discussion | # OO/PC/Pharmacy Joint Discussion | ||
Line 205: | Line 208: | ||
<!-- **** Delete instructions and fill in minutes ON NEXT LINES ******--> | <!-- **** Delete instructions and fill in minutes ON NEXT LINES ******--> | ||
− | === | + | === Joint Discussion PC/OO/Pharmacy === |
− | + | ==== Background ==== | |
− | + | Recurring questions about how to handle biologically derived products (e.g. blood, tissue, organ) as well as procedures that are dosed (e.g. radiation-therapy, light therapy) | |
+ | * [https://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=8458 GF#8458] Is a blood transfusion closer to a medication administration or a procedure, or something else? | ||
+ | * [http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=12993 GF#12993] Please Create a NonMedicationAdministration object or an Administration object | ||
* [http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=12673 GF#12673] How to handle HCT/TP | * [http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=12673 GF#12673] How to handle HCT/TP | ||
− | * [http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id= | + | ** [http://build.fhir.org/extension-device-din.html extension-device-din] says |
+ | *** The distinct identification code required by §1271.290(c) for a human cell, tissue, or cellular and tissue-based product (HCT/P) regulated as a device - which is a conditional, variable portion of the production identifier (PI) of a Unique device Identifier (UDI). If the content is from an ICCBBA-encoded UDI, the URI to use for the system is: http://hl7.org/fhir/NamingSystem/iccbba-din. GS1 and HIBCC formatted UDIs do not currently convey the DIN element. | ||
+ | *** Note to balloters: The Orders and Observations Workgroup has not yet determined whether the Device resource will include Devices of Human (or other) Origin (tissue, blood, etc.) and so the need for Donation Identification number is currently being met through this extension. If it is determined a separate resource is to be used for Devices of Human (or other) Origin (tissue, blood, etc.) then this extension may be deprecated in the future. Feedback on this issue is welcome. | ||
+ | ** Per [http://lists.hl7.org/read/messages?id=288143 Feb 2016 OO ListServ] discussing [https://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=9449 GF#9449], proposed boundaries included | ||
+ | *** '''Device''': a manufactured item that is used in the provision of healthcare without being substantially changed through that activity. The device may be a medical or non-medical device | ||
+ | *** '''Substance''': A homogeneous material with a definite composition | ||
+ | *** '''BiologicallyDerivedProduct''': material extracted from a living mammalian organism or that is still living | ||
+ | * [[2017-04-13_Patient_Care_FHIR_Call]] | ||
+ | ** NMDP (National Marrow Donor Program) and CIBTMR (Center for International Blood and Marrow Transplant Research) would like to participate in helping develop a new resource for transplant material | ||
+ | ** It would include things like bone marrow, cord blood, peripheral blood stem cells - and any new resource could also address solid organs and blood transfusion although not part of the initial use case | ||
+ | ** Align with scope of ISBT128, the purpose of which is: to provide standards and guidance for the coding and labeling of medical products of human origin (MPHO): blood, cellular therapy, tissues, regenerated tissue, milk, fecal microbiota, topical products of human origin, in vivo diagnostic MPHO, and organs for transplant, as well as those plasma derivatives for which ABO is relevant. (we may want to extend the scope to “biological origin” rather than limiting to “human origin”) | ||
+ | |||
* [http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=13047 GF#13047] and [https://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=12966 GF#12966] Add DosageInstructions to Procedure/ProcedureRequest | * [http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=13047 GF#13047] and [https://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=12966 GF#12966] Add DosageInstructions to Procedure/ProcedureRequest | ||
** [https://chat.fhir.org/#narrow/stream/implementers/topic/Radiation.20therapy Radiology Therapy discussion on Zulip] | ** [https://chat.fhir.org/#narrow/stream/implementers/topic/Radiation.20therapy Radiology Therapy discussion on Zulip] | ||
** [https://chat.fhir.org/#narrow/stream/implementers/subject/Blood.2C.20Tissue.2C.20Organ.3A.20Donation Blood, Tissue, Organ Donation on Zulip] | ** [https://chat.fhir.org/#narrow/stream/implementers/subject/Blood.2C.20Tissue.2C.20Organ.3A.20Donation Blood, Tissue, Organ Donation on Zulip] | ||
+ | ==== Discussion ==== | ||
+ | * Topics | ||
+ | ** blood transfusion | ||
+ | ** blood products | ||
+ | ** human cell, tissue, or cellular and tissue-based product (HCT/P) | ||
+ | ** grafts | ||
+ | ** bone marrow | ||
+ | ** cord blood | ||
+ | ** peripheral blood stem cells | ||
+ | ** solid organs | ||
+ | ** blood transfusion | ||
+ | ** blood | ||
+ | ** cellular therapy | ||
+ | ** tissues | ||
+ | ** regenerated tissue | ||
+ | ** milk | ||
+ | ** fecal microbiota | ||
+ | ** topical products of human origin | ||
+ | ** in vivo diagnostic MPHO | ||
+ | ** organs for transplant | ||
+ | ** plasma derivatives for which ABO is relevant | ||
+ | ** bio-fabricated products or materials (e.g. stem cells embedded) | ||
+ | |||
+ | * Should we focus on blood products initially? | ||
+ | ** Does MedicationAdministration fit? | ||
+ | * John said charting of meds/blood products is typically done using the same workflow | ||
+ | * Mike mentioned that blood products may require additional verification, but John said TPNs can also have similar requirements | ||
+ | * Dan is working on IHE profiles - doesn't focus on supply, but rather patient workflows | ||
+ | * Type and cross match order is a lab order - not handled by pharmacy - but that's ok | ||
+ | * Blood Bank - want 2 units | ||
+ | * Mike mentioned that there can be 2 orders (blood product, itself, provided by blood bank as well as the transfusion order to actually do the administration). In OR, may order it, but not use it. Question: whether the transfusion order is (or needs to be) a pharmacy order. | ||
+ | * Blood Bank will look to match transfusion against volume of blood ordered. Transfusion is more like a nursing order more so than pharmacy order. | ||
+ | * Some agreement to use MedicationRequest for the transfusion, but more discussion needed (especially for the type/cross) | ||
+ | * Orders may be written at the same time, but transfusion must wait on typing and cross-matching. | ||
+ | * Prepare order doesn't refer to specific unit (nor does transfusion), but administration would have specific unit | ||
+ | * Standing orders to give O negative (trauma patients) until orders are received to give same blood type | ||
+ | |||
+ | * Radiation therapy agents (i.e. contrast administration) may have similarities with MedicationAdministration | ||
+ | * Prescribing (dosing) radiation therapy is different and Pharmacy hasn't considered whether it is in scope or not | ||
+ | |||
+ | * Breastmilk and donor breastmilk - is that a nutritional order? | ||
+ | |||
+ | * Workflow steps: Test > Prepare > Request Dispense > Dispense Issue > Administration | ||
+ | |||
+ | ==== Follow-up Needed ==== | ||
+ | * Eric will sync with Margaret regarding donor breastmilk (consider donor extensions) in context of nutrition orders | ||
+ | * Michelle will create Wiki page for brainstorming use cases and workflow -- [[Patient_Care_Blood_Products_and_Transfusions]] | ||
+ | * What is being done in the real world? | ||
+ | ** For blood products, what data elements are collected? Goal is to assess gaps in resources. | ||
+ | ** Request use cases from implementers. | ||
+ | |||
+ | ==== Decisions ==== | ||
+ | Resource and Work Group Aligmment | ||
+ | * How to represent blood products? Substance - but MedicationRequest will need to reference Substance directly | ||
+ | * Order | ||
+ | ** Workflow 1: | ||
+ | *** Type and Cross -- ProcedureRequest | ||
+ | *** Transfusion of X Units -- MedicationRequest | ||
+ | ** Workflow 2: | ||
+ | *** Type and Screen | ||
+ | *** Cross match later | ||
+ | *** Transfusion Order | ||
+ | * How to represent dispense of product from blood bank? MedicationDispense | ||
+ | * How to represent statement from patient that patient has received blood products? MedicationStatement | ||
+ | * How to represent transfusion "event"? MedicationAdministration | ||
+ | |||
+ | === WGM Planning === | ||
+ | Patient Care WGM agenda: [[PC_Sept_2017_WGM]] | ||
+ | <br> | ||
+ | Continue the Blood Product / Transfusion discussion on Wed Q3 | ||
+ | |||
+ | <br> | ||
SOAP / ClinicalImpression | SOAP / ClinicalImpression | ||
* [http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=12676 GF#12676] Guidance request for GP SOAP in FHIR (Alexander Henket) - | * [http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=12676 GF#12676] Guidance request for GP SOAP in FHIR (Alexander Henket) - | ||
− | + | * https://chat.fhir.org/#narrow/stream/implementers/topic/ClinicalImpression | |
− | |||
=== Adjourn === | === Adjourn === | ||
− | Adjourned at | + | Adjourned at 6:30pm Eastern. |
==Meeting Outcomes== | ==Meeting Outcomes== | ||
Line 239: | Line 326: | ||
| width="100%" align="left" style="background:#f0f0f0;"|'''Actions''' '' | | width="100%" align="left" style="background:#f0f0f0;"|'''Actions''' '' | ||
− | * | + | * Eric will sync with Margaret regarding donor breastmilk (consider donor extensions) in context of nutrition orders |
+ | * Michelle will create Wiki page for brainstorming use cases and workflow | ||
+ | * What is being done in the real world? | ||
|- | |- |
Latest revision as of 22:45, 10 August 2017
Contents
Meeting Information
Patient Care FHIR Resources Conference Call Location: Conference Call |
Date: 2017-08-10 Time: 5-6:30pm ET | ||
Facilitator | Michelle M Miller | Note taker(s) | Michelle M Miller |
Attendee | Name | Affiliation
| |
X | Elaine Ayres | NIH/Department of Clinical Research Informatics | |
X | Dave Carlson | VA | |
X | Stephen Chu | The Australian Digital Health Agency (ADHA) | |
Evelyn Gallego | EMI Advisors LLC | ||
X | Eric Haas | Haas Consulting | |
X | Rob Hausam | Hausam Consulting LLC | |
X | Laura Heermann-Langford | Intermountain Healthcare | |
X | Emma Jones | Allscripts | |
Russ Leftwich | InterSystems | ||
X | Tony Little | Optum 360 | |
X | Jay Lyle | Ockham Information Services LLC, VA | |
Russell McDonell | Telstra Health | ||
Lloyd McKenzie | Gevity (HL7 Canada) | ||
Larry McKnight | Cerner | ||
X | Michelle M Miller | Cerner | |
Lisa Nelson | Life Over Time Solutions | ||
Viet Nguyen | Lockheed Martin, Systems Made Simple | ||
M'Lynda Owens | Cognosante | ||
X | Mike Padula | The Children's Hospital of Philadelphia | |
Craig Parker | Intermountain Healthcare | ||
X | Joe Quinn | Optum | |
Simon Sum | Academy of Nutrition and Dietetics | ||
Iona Thraen | Dept of Veterans Affairs | ||
Serafina Versaggi | Dept of Veterans Affairs | ||
Buitendijk,Hans | Cerner | ||
JD Nolen | |||
Kenneth McCaslin | Accenture | ||
Lorraine Constable | |||
Patrick Loyd | |||
Riki Merrick | |||
X | Melva Peters | Gevity | |
X | John Hatem | ||
Jean Duteau | |||
X | Scott Robertson | ||
Jose Costa Teixeira | |||
Grahame Grieve | |||
X | Daniel Rutz | ||
Quorum Requirements Met: yes |
Agenda
Agenda Topics
- Agenda review
- Approve previous meeting minutes 2017-08-03_Patient_Care_FHIR_Call
- Motion: Stephen/Eric
- OO/PC/Pharmacy Joint Discussion
Supporting Information
- Tracker Issues - https://docs.google.com/a/lmckenzie.com/uc?id=0B285oCHDUr09Mzh3b09rMFhEV1E
- Resolve QA Warnings to have resource FMM > 0
- Resolve QA Information messages to achieve FMM = 3
- Maintain QA checklist
Minutes
Joint Discussion PC/OO/Pharmacy
Background
Recurring questions about how to handle biologically derived products (e.g. blood, tissue, organ) as well as procedures that are dosed (e.g. radiation-therapy, light therapy)
- GF#8458 Is a blood transfusion closer to a medication administration or a procedure, or something else?
- GF#12993 Please Create a NonMedicationAdministration object or an Administration object
- GF#12673 How to handle HCT/TP
- extension-device-din says
- The distinct identification code required by §1271.290(c) for a human cell, tissue, or cellular and tissue-based product (HCT/P) regulated as a device - which is a conditional, variable portion of the production identifier (PI) of a Unique device Identifier (UDI). If the content is from an ICCBBA-encoded UDI, the URI to use for the system is: http://hl7.org/fhir/NamingSystem/iccbba-din. GS1 and HIBCC formatted UDIs do not currently convey the DIN element.
- Note to balloters: The Orders and Observations Workgroup has not yet determined whether the Device resource will include Devices of Human (or other) Origin (tissue, blood, etc.) and so the need for Donation Identification number is currently being met through this extension. If it is determined a separate resource is to be used for Devices of Human (or other) Origin (tissue, blood, etc.) then this extension may be deprecated in the future. Feedback on this issue is welcome.
- Per Feb 2016 OO ListServ discussing GF#9449, proposed boundaries included
- Device: a manufactured item that is used in the provision of healthcare without being substantially changed through that activity. The device may be a medical or non-medical device
- Substance: A homogeneous material with a definite composition
- BiologicallyDerivedProduct: material extracted from a living mammalian organism or that is still living
- extension-device-din says
- 2017-04-13_Patient_Care_FHIR_Call
- NMDP (National Marrow Donor Program) and CIBTMR (Center for International Blood and Marrow Transplant Research) would like to participate in helping develop a new resource for transplant material
- It would include things like bone marrow, cord blood, peripheral blood stem cells - and any new resource could also address solid organs and blood transfusion although not part of the initial use case
- Align with scope of ISBT128, the purpose of which is: to provide standards and guidance for the coding and labeling of medical products of human origin (MPHO): blood, cellular therapy, tissues, regenerated tissue, milk, fecal microbiota, topical products of human origin, in vivo diagnostic MPHO, and organs for transplant, as well as those plasma derivatives for which ABO is relevant. (we may want to extend the scope to “biological origin” rather than limiting to “human origin”)
Discussion
- Topics
- blood transfusion
- blood products
- human cell, tissue, or cellular and tissue-based product (HCT/P)
- grafts
- bone marrow
- cord blood
- peripheral blood stem cells
- solid organs
- blood transfusion
- blood
- cellular therapy
- tissues
- regenerated tissue
- milk
- fecal microbiota
- topical products of human origin
- in vivo diagnostic MPHO
- organs for transplant
- plasma derivatives for which ABO is relevant
- bio-fabricated products or materials (e.g. stem cells embedded)
- Should we focus on blood products initially?
- Does MedicationAdministration fit?
- John said charting of meds/blood products is typically done using the same workflow
- Mike mentioned that blood products may require additional verification, but John said TPNs can also have similar requirements
- Dan is working on IHE profiles - doesn't focus on supply, but rather patient workflows
- Type and cross match order is a lab order - not handled by pharmacy - but that's ok
- Blood Bank - want 2 units
- Mike mentioned that there can be 2 orders (blood product, itself, provided by blood bank as well as the transfusion order to actually do the administration). In OR, may order it, but not use it. Question: whether the transfusion order is (or needs to be) a pharmacy order.
- Blood Bank will look to match transfusion against volume of blood ordered. Transfusion is more like a nursing order more so than pharmacy order.
- Some agreement to use MedicationRequest for the transfusion, but more discussion needed (especially for the type/cross)
- Orders may be written at the same time, but transfusion must wait on typing and cross-matching.
- Prepare order doesn't refer to specific unit (nor does transfusion), but administration would have specific unit
- Standing orders to give O negative (trauma patients) until orders are received to give same blood type
- Radiation therapy agents (i.e. contrast administration) may have similarities with MedicationAdministration
- Prescribing (dosing) radiation therapy is different and Pharmacy hasn't considered whether it is in scope or not
- Breastmilk and donor breastmilk - is that a nutritional order?
- Workflow steps: Test > Prepare > Request Dispense > Dispense Issue > Administration
Follow-up Needed
- Eric will sync with Margaret regarding donor breastmilk (consider donor extensions) in context of nutrition orders
- Michelle will create Wiki page for brainstorming use cases and workflow -- Patient_Care_Blood_Products_and_Transfusions
- What is being done in the real world?
- For blood products, what data elements are collected? Goal is to assess gaps in resources.
- Request use cases from implementers.
Decisions
Resource and Work Group Aligmment
- How to represent blood products? Substance - but MedicationRequest will need to reference Substance directly
- Order
- Workflow 1:
- Type and Cross -- ProcedureRequest
- Transfusion of X Units -- MedicationRequest
- Workflow 2:
- Type and Screen
- Cross match later
- Transfusion Order
- Workflow 1:
- How to represent dispense of product from blood bank? MedicationDispense
- How to represent statement from patient that patient has received blood products? MedicationStatement
- How to represent transfusion "event"? MedicationAdministration
WGM Planning
Patient Care WGM agenda: PC_Sept_2017_WGM
Continue the Blood Product / Transfusion discussion on Wed Q3
SOAP / ClinicalImpression
- GF#12676 Guidance request for GP SOAP in FHIR (Alexander Henket) -
- https://chat.fhir.org/#narrow/stream/implementers/topic/ClinicalImpression
Adjourn
Adjourned at 6:30pm Eastern.
Meeting Outcomes
Actions
|
Next Meeting/Preliminary Agenda Items
|
© 2012 Health Level Seven® International. All rights reserved.